DecisionDx-SCC

Castle will share new data on its DecisionDx?-Melanoma and DecisionDx?-SCC tests for patients with skin cancers at the 2025 AAD Annual Meeting, taking place March 7-11 in Orlando, Florida. New study corroborates DecisionDx-SCC's ability to independently predict metastatic risk in patients with high-risk cutaneous squamous cell carcinoma (SCC) Landmark analysis of nearly 10,000 patients through Castle's collaboration with the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program Registries showed a significant association between DecisionDx-Melanoma testing and improved survival in melanoma patients. Further highlights: https://hubs.la/Q039XQgL0

Stop by our booth (#1661) tomorrow through Sunday at the #AAD2025 Annual Meeting. Grab a coffee and win prizes by playing Whac-A-Mole! DecisionDx-Melanoma | DecisionDx-SCC | MyPath Melanoma

Exciting week ahead for us here at Castle! We are heading to Orlando for the following conferences and look forward to connecting with you. See you all soon! DecisionDx-Melanoma DecisionDx-SCC MyPath Melanoma

Castle will share data supporting its dermatologic portfolio of gene expression profile (GEP) tests — DecisionDx?-Melanoma, DecisionDx?-SCC, and MyPath? Melanoma — at the 2025 Winter Clinical Dermatology Conference - Hawaii, taking place Feb. 14-19 in Waikoloa Village, Hawaii. Details: https://hubs.ly/Q036B7Rw0

Emily Ruiz, MD, MPH, the Academic Director of the Mohs and Dermatologic Surgery Center at Brigham and Women’s Hospital in Boston, MA, reviews topline data from a late-breaking abstract showing that Castle Biosciences, Inc.’s DecisionDx-SCC test improved the accuracy of metastatic risk prediction in patients with cutaneous squamous cell carcinoma (SCC) tumors on the head or neck. Dr. Ruiz also shares clinical scenarios where this 40-gene expression profile test can help guide treatment decisions. Watch here: https://hubs.la/Q037zJQn0

Castle will share data supporting its dermatologic portfolio of gene expression profile (GEP) tests — DecisionDx?-Melanoma, DecisionDx?-SCC, and MyPath? Melanoma — at the 2025 Winter Clinical Dermatology Conference - Hawaii, taking place Feb. 14-19 in Waikoloa Village, Hawaii. Details: https://hubs.ly/Q036BdGz0

Castle Biosciences, Inc.’s DecisionDx-SCC test improves risk stratification of patients with cutaneous squamous cell carcinoma (SCC) tumors located on the head or neck when the test’s results are combined with Brigham and Women's Hospital (BWH) staging, new research shows. https://lnkd.in/d_V3j7_P

Join us this morning to learn more about how DecisionDx-SCC risk stratifies patients with head and neck squamous cell carcinoma and the prognostic value of adding the test to BWH staging! Castle Biosciences’ poster on DecisionDx-SCC was selected as a “Late Breakers” Top Five Finalist for the Akamai Award, recognizing the best posters at Maui Derm Hawaii 2025. Highlights of the data will be shared by Dr. Emily Ruiz in a podium presentation during the Late Breakers session. See you there! #MauiDermHawaii

Castle will share data supporting its dermatologic portfolio of tests for skin cancer — DecisionDx-SCC, DecisionDx?-Melanoma, and MyPath? Melanoma — through poster presentations at Maui Derm Hawaii, being held Jan. 20-24. As a “Late Breaker” Five finalist, Castle’s DecisionDx-SCC poster will also be highlighted in a special podium presentation on Tuesday, Jan. 21, at 10:45 a.m. local time. Details: https://hubs.la/Q032_XN30

Making the most innovative and reliable genomic tests available to physicians and patients in Israel is Oncotest's goal. What better way to achieve that goal than by bringing the strongest independent predictor of metastasis in patients diagnosed with Cutaneous Squamous Cell Carcinoma (cSCC) to the hands of doctors. Up until now, there were no genomic tests for patients diagnosed with cSCC. Physicians relied solely on clinical-pathological features to make clinical management decisions. DecisionDx-SCC by Castle Biosciences, Inc. is a validated genomic test, based on the biological profile of 40 genes. It is designed to identify the biological risk of metastasis and inform treatment and management decisions for patients diagnosed with cSCC. This week Oncotest had the pleasure of introducing this innovative technology to teams of oncologists and surgeons at Sheba and Soroka Medical Centers. And this is only the beginning… For more information, visit our website: https://lnkd.in/diuymmdc #SCC #Oncology #Genomics #Personalized_Medicine